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Objective: Deficiencies of vitamin A and iodine are common in many developing countries. Vitamin A defi-
ciency (VAD) may adversely affect thyroid metabolism. The study aim was to investigate the effects of con-
current vitamin A and iodine deficiencies on the thyroid–pituitary axis in rats. Design: Weanling rats (n  56)
were fed diets deficient in vitamin A (VAD group), iodine (ID group), vitamin A and iodine (VAD  ID group),
or sufficient in both vitamin A and iodine (control) for 30 days in a pair-fed design. Serum retinol (SR), thy-
roid hormones (FT4, TT4, FT3, and TT3), serum thyrotropin (TSH), pituitary TSH mRNA expression levels,
and thyroid weights were determined at the end of the depletion period. Main outcome: Compared to the con-
trol and ID groups, SR concentrations were about 35% lower in the VAD and VAD  ID groups (p  0.001),
indicating moderate VA deficiency. Comparing the VAD and control groups, there were no significant differ-
ences in TSH, TSH mRNA, thyroid weight, or thyroid hormone levels. Compared to the control group, serum
TSH, TSH mRNA, and thyroid weight were higher (p  0.05), and FT4 and TT4 were lower (p  0.001), in the
VAD  ID and ID groups. Compared to the ID group, TSH, TSH mRNA, and thyroid weight were higher
(p  0.01) and FT4 and TT4 were lower (p  0.001) in the VAD  ID group. There were no significant differ-
ences in TT3 or FT3 concentrations among groups. Conclusion: Moderate VAD alone has no measurable effect




VITAMIN A DEFICIENCY (VAD) and iodine deficiency (ID)are major global public health problems, affecting more
than 30% of the population worldwide (1). In many regions
of the developing world, vulnerable groups, such as young
women, infants, and children, suffer from both VAD and ID
(2,3). In areas of endemic goiter, micronutrient status is an
important determinant of iodine and thyroid metabolism (4).
Deficiencies of selenium (5) and iron (2) can act in concert
with iodine deficiency to impair thyroid metabolism and
modify the response to prophylactic iodine (6,7).
In animals, VAD has multiple effects on thyroid metabo-
lism. Severe VAD decreases thyroidal iodine uptake, impairs
thyroglobulin (Tg) synthesis, and increases thyroid size (8,9).
In the periphery, VAD increases free and total circulating
thyroid hormone (10–13), and binding of transthyretin (TTR)
to retinol-binding protein (RBP) decreases VA turnover and
enhances VA delivery (14,15). Centrally, because retinoic
acid suppresses transcription of the pituitary TSH gene
through activation of the retinoid X receptor (RXR) (16–18),
VA status may modulate thyroxine (T4) feedback of thy-
rotropin (TSH) secretion. VAD in rats increases pituitary
TSH mRNA and TSH secretion; both return to normal af-
ter treatment with retinoic acid (19).
In a recent study in African children with ID and VAD,
increasing VAD severity was a predictor of greater thyroid
volume and higher concentrations of TSH and T4 (3). This
study suggested that VAD in goitrous children increases
TSH stimulation and thyroid size, and reduces risk for hy-
pothyroidism, an effect that could be due to modulation of
the pituitary TSH gene by VA (3). Therefore, the aim of this
study was to investigate the effects of concurrent VAD and
ID on the thyroid–pituitary axis in rats.
Materials and Methods
Animals and diets
The Veterinary Office of the Canton of Zurich’s Depart-
ment of Health gave the ethical approval for the study. Male
weanling Sprague–Dawley rats (n  56; Charles River
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GmbH, Germany) at 21  3 days of age were housed indi-
vidually in random order in stainless steel cages with grated
stainless steel floors. The rats were kept under controlled
conditions at 21°C and 55% humidity with a 12-hour
light:dark cycle. Rats consumed Millipore water (Milli-Q UF
Plus, Millipore, Bedford, MA) ad libitum. The diets were pre-
pared by Dyets Inc. (Bethlehem, PA) following the AIN-93G
purified rodents guidelines (20), and were based on L-amino
acids to avoid iodine contamination from casein as a major
protein source.
Study design
The depletion period lasted 30 days. The rats (n  8 in each
group) were randomly divided into seven groups: a control
group fed a VA- and iodine-sufficient diet (control group),
a group fed the VA-deficient diet (VAD group), a group fed
the iodine-deficient diet (ID group), and a group fed the VA
and iodine-deficient diet (VAD  ID group). Animals in the
VAD, ID, and VAD  ID groups were matched to pair-fed
animals fed the control diet (n  8 in each of the three pair-
fed groups). All animals were handled daily to reduce stress
at blood collection and sacrifice. Food intake was recorded
daily and the body weight was measured three times per
week. Blood was collected by tail vain incision (21) and
serum was stored at 20°C. After the animals were killed
by decapitation, the thyroid and pituitary were immediately
dissected and removed. Thyroid dissection was done using
a dissecting microscope under supervision of an experienced
animal technician. Thyroids were weighed immediately af-
ter dissection, and then wrapped in aluminum foil, shock
frozen in liquid nitrogen, and stored at 60°C. The pitu-
itaries were dissected within 60 seconds and stored in
RNAlater solution (RNeasy Protect Mini Kit, cat. no. 74104,
Qiagen GmbH Hilden, Germany) at –60°C.
Laboratory analysis
Free and total thyroxine and triiodothyronine (FT4, TT4, FT3,
and TT3) and serum TSH were measured using immuno-
chemiluminescent assays (IMMULITE®, Buehlmann Labora-
tories AG, Switzerland). Serum retinol (SR) was measured
with an optimized high-pressure liquid chromatography
method (22,23). For measurement of TSH mRNA, total RNA
extraction was done using the RNeasy Protect Mini Kit (Qia-
gen GmbH, Hilden, Germany), with samples stored after each
working step at –80°C. To avoid DNA contamination, a DNA
on column digestion was carried out during the total RNA ex-
traction (RNase-free DNase set, cat. no. 79252, Qiagen GmbH
Hilden, Germany). TSH mRNA expression levels were mea-
sured with SYBR-Green® one-step RT-qPCR (QuantiTect
SYBR Green RT-PCR Kit, cat. no. 204243, Qiagen GmbH,
Hilden, Germany) using an ABI Prism 7900 Thermocycler
(Applied Biosystems, Foster City, CA). The specific primer
pairs were purchased from Qiagen, Germany. TSH mRNA
expression levels were normalized with a housekeeping gene
(Hrpt). For each animal, five replicates for the target gene and
three replicates for the housekeeping gene were performed.
Statistical analysis
Data processing and analysis were done using SPSS 13.0
(SPSS Chicago, IL) and Microsoft Excel 2002 (Seattle, WA).
Data not normally distributed (TSH) were log transformed be-
fore comparisons. Comparisons between the treatment groups
were done with analysis of variance. If the interaction effect
was significant, t tests were done and adjusted for multiple
comparisons (Bonferroni). Significance was set at p  0.05.
Results
Compared to the control group, there was no significant
difference in any of the measured biochemical or anatomic
variables in the pair-fed groups (data not shown). Food in-
take and body weights (grams) did not differ significantly in
all treatment groups; body weights were as follows: control
267  16, VAD 258  17, ID 260  14, VAD  ID 281  25.
As shown in Table 1, compared to the ID and control groups,
SR concentrations were about 35% lower in the VAD and
VAD  ID groups (p  0.001), indicating moderate VA defi-
ciency. There was no significant difference in SR comparing
the VAD  ID and VAD groups.
Serum concentrations of TSH, TT3, FT3, TT4, and FT4, and
thyroid weights among the groups are shown in Table 1.
Levels of pituitary TSH mRNA among the groups are
shown in Figure 1. Comparing VAD to control, there was no
significant difference in TT3, FT3, TT4, or FT4. In ID and ID 
VAD groups, FT4 and TT4 were lower compared to the con-
trol group (p  0.001). FT4 and TT4 were lower in the ID 
VAD group compared to the ID group (p  0.05). There were
no significant differences in TT3 or FT3 concentrations be-
tween the groups. Mean TSH, TSH mRNA, and thyroid
weight were significantly greater in the VAD  ID and ID
groups compared to the control group (p  0.05). TSH, TSH
mRNA, and thyroid weight were significantly greater in the
VAD  ID group compared to the ID group (p  0.01).
Discussion
Our findings demonstrate that combined deficiencies of
VA and iodine have greater adverse effects on the pitu-
itary–thyroid axis compared to single deficiencies of VA or
iodine. The data from the pair-fed controls indicate that these
changes were not due to reduced food intake. Compared to
the ID group, TSH, TSH mRNA, and thyroid weight were
30% higher in the VAD  ID group. Compared to the ID
group, FT4 and TT4 were reduced by 50% and 75%, re-
spectively, in the VAD  ID group. Thus, concurrent VAD
aggravates ID-induced primary hypothyroidism.
There are several potential mechanisms that could explain
this effect. In iodine-sufficient animals, severe VAD alone
causes thyroid hypertrophy (9,24), reduces thyroidal iodine
uptake (25), impairs synthesis of Tg and coupling of iodoty-
rosine residues to form thyroid hormone (8), and decreases
intrathyroidal T3 and T4 (8,9). In the periphery, severe VAD
increases total and free T3 and T4 (8,10), reduces hepatic con-
version of T4 to T3 (8,26), and decreases T3 uptake and bind-
ing (11,12). Because we did not measure deiodinase expres-
sion and/or activity in the thyroid or the liver, this study
does not provide data on these potential mechanisms.
Although we did not measure thyroid binding proteins or
binding affinity in this study, VAD may affect thyroid me-
tabolism through shared transport proteins. In humans, thy-
roid-binding globulin (TBG) carries the majority of T4 and
T3 in plasma (ca. 70%), whereas TTR binds 10–15% (14). Rats
lack TBG and show different binding ratios between thyroid
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transport proteins (27). In rats and humans, TTR is a primary
indirect carrier of VA; RBP is secreted from the hepatocyte
as a complex with TTR, and binding of RBP to TTR prevents
renal clearance of RBP, thereby enhancing VA delivery
(28,29). Although VAD decreases hepatic release of RBP, re-
lease of TTR and serum TTR concentrations are similar dur-
ing vitamin A depletion and repletion in rats (30,31). How-
ever, animal studies have suggested binding capacity and
affinity of TTR for thyroid hormone may be modified by in-
teraction with RBP (28,32–34).
VAD may also affect thyroid metabolism through a cen-
tral mechanism. Both the thyroid hormone–activated thyroid
receptor and the retinoic acid–activated retinoid X receptor
suppress transcription of the pituitary TSH gene by occu-
pying half-sites on the promotor DNA of the gene (16–18).
Breen et al. (19) found that severe VAD in rats increased pi-
tuitary TSH mRNA levels twofold, and increased serum
TT4; both returned to normal after VA treatment. They con-
cluded that the increased TSH mRNA despite high serum
TT4 implied VAD had made the pituitary thyrotrope rela-
tively insensitive to feedback control by thyroid hormone. In
pair-fed rats with VAD, Morley et al. (10) also found an in-
crease in hypothalamic thyrotropin-releasing hormone and
pituitary TSH despite high circulating thyroid hormone. In
contrast to these previous studies in severely VA-deficient
rats, where higher TSH concentrations in the face of higher
circulating TT4 suggest central resistance to normal TSH
suppression by thyroid hormone, our data suggest that mod-
erate VAD alone does not adversely affect the pituitary–thy-
roid axis.
To our knowledge, this is the first study to demonstrate
that VAD in the presence of ID enhances the overexpression
of TSH that is characteristic of ID. Mean TSH mRNA was
more than 100% higher in the VAD  ID group compared
to the ID group. Increased expression of TSH was likely
due to aggravation of primary hypothyroidism; that is, lower
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TABLE 1. MEAN VALUES  SD FOR SERUM RETINOL, TSH, THYROID WEIGHT, AND THYROID HORMONE CONCENTRATIONS
IN WEANLING RATS FED DIETS DEFICIENT IN VITAMIN A (VAD GROUP), IODINE (ID GROUP), VITAMIN A 
AND IODINE (VAD  ID GROUP), OR SUFFICIENT IN BOTH VITAMIN A AND IODINE (CONTROL) FOR 30 DAYS
Control VAD ID VAD  ID
Serum retinol (g/dL) 52.71  5.93 33.93  3.61a 51.70  4.73 31.61  2.33a
TSH (mIU/mL)* 0.13  0.35 0.14  0.11 0.29  0.11b,d 0.77  0.30b,d
Thyroid weight (mg) 17.5  2.2 14.2  3.1 26.4  5.9b,d 37.8  9.4b,d
TT4 (g/dL) 6.56  0.65 6.60  0.62 3.98  1.37c,d 1.16  0.31c,d
FT4 (ng/dL) 3.27  0.46 3.35  0.36 2.06  0.60c,d 0.95  0.44c,d
TT3 (ng/dL) 135.36  18.49 135.71  20.69 124.36  22.42 107.47  16.93
FT3 (pg/mL) 5.64  0.67 5.80  1.59 4.60  1.12 5.10  0.86
*Data were log transformed for statistical analysis.
aSignificantly different from control and ID group (p  0.001; ANOVA, post-hoc test: Bonferroni).
b,cSignificantly different from control and VAD group (bp  0.05, cp  0.01; ANOVA, post-hoc test: Bonferroni).
dSignificantly different between ID and VAD  ID group (p  0.01; ANOVA, post-hoc test: Bonferroni).
FIG. 1. Pituitary thyrotropin  mRNA concentrations in weanling rats fed diets deficient in vitamin A (VAD group), io-
dine (ID group), vitamin A and iodine (VAD  ID group), or sufficient in both vitamin A and iodine (control) for 30 days.
a: Significantly different from control group (p  0.05; ANOVA, post-hoc test: Bonferroni). b: Significantly different between
ID and VAD  ID group (p  0.01; ANOVA, post-hoc test: Bonferroni).
circulating T4 levels in the VAD  ID group compared to the
ID group stimulated greater TSH mRNA production. It is
also possible that VAD, in the setting of ID, enhanced TSH
mRNA expression through reduced suppression by the thy-
roid hormone–activated thyroid receptor and the retinoic
acid (RA)-activated retinoid X receptor of the pituitary TSH
gene. Haugen et al. (18), in an in vitro study, reported that
both T3 and RA independently suppress promotor activity.
Li et al. (35,36) have suggested that the retinoid X receptor
(RXR) component in a thyroid hormone receptor TR/RXR
heterodimer is not a silent partner, but has important regu-
latory effects on the expression of the pituitary TSH gene.
One previous study examined the effect of concurrent
VAD  ID in rats. Ingenbleek (8) provided rats either iodine-
deficient (ID), vitamin A–deficient (VAD), or iodine and vit-
amin A–deficient (ID  VAD) diets for 60 days. Concentra-
tions of FT4 and TT4 were greater in the VAD group, lower
in the ID group, and intermediate in the VAD  ID group,
compared to control. Serum TSH and TT3 concentrations
were increased in both the ID and the VAD  ID group. In
the VAD and VAD  ID groups, synthesis of Tg and cou-
pling of iodotyrosine residues to form thyroid hormone was
impaired, and it was suggested that this was the primary
cause of the adverse effects of VAD on thyroid metabolism
(8). These data differ from our findings; in our study, VAD
alone had no effect on thyroid metabolism, and there was no
change in T3 levels and a significant decrease in T4 in the
VAD  ID group. Differences in study design likely explain
the varying findings between the two studies. The depletion
period was twice as long in the study by Ingenbleek, and
serum retinol levels fell to 10% of the control group, indicat-
ing severe VAD. Also, the rats were not pair-fed in that study
(8), and significant decreases in body weight in the VAD and
VAD  ID groups may have confounded the results.
The results of the present study differ somewhat from the
findings of our previous study in African children with ID
and VAD, where increasing VAD severity was a predictor
of greater thyroid volume and higher concentrations of TSH
and T4 (3). Both studies found an increase in TSH concen-
tration and thyroid size in concurrent ID and VAD, but in
the present study, thyroid hormone concentrations were de-
creased. This difference could be due to several factors, in-
cluding differences in study design, varying degrees of VAD,
and/or confounding factors in the human, cross-sectional
study, such as other nutritional deficiencies in the children.
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